Neal Shore, MD, discusses the complexity of prostrate cancer and factors to consider when determining management strategies.
Advanced Prostate Cancer: PSMA-Targeted Radioligand Therapies
A discussion of phenotypic and genotypic biomarkers found in prostate cancer and their implications.
An overview of the diagnostic and therapeutic applications of PSMA in prostate cancer is presented.
Dr Neal Shore explains the clinical implications of PSMA PET scans in advanced prostate cancer.
Results of the phase 3 VISION study of 177Lu-PSMA PET in advanced prostate cancer are described.
Highlights of potential future applications of PSMA ligand–directed therapies in prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5